Skip to main content

2 Result(s)

within Yu-Luan Chen Remove this filter Internal Medicine Remove this filter

and

  1. Article

    Open Access

    A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

    Ulotaront is a novel psychotropic agent with agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A) receptors in phase III clinical development for the treatment of...

    Hironobu Tsukada, Yu-Luan Chen, Guangqing **ao, Lisa Lennek… in Clinical Pharmacokinetics (2023)

    Download PDF (695 KB) View Article

  2. Article

    Open Access

    Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans

    Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT1A receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bio...

    Yu-Luan Chen, Hironobu Tsukada, Snezana Milanovic, Lei Shi, Yan Li… in Neurology and Therapy (2023)

    Download PDF (1142 KB) View Article